Immuron hosts a proprietary technology platform that develops specific oral antibodies to address urgent medical needs.
Immuron is a publicly listed Australian biopharmaceutical company whose crucial oral antibodies can help combat the growing threat of antimicrobial resistance.
Orally-delivered antibodies specifically target enteric pathogens in the GI tract, preventing their attachment to the intestinal wall.
Immuron’s oral-targeted therapeutics offer significant advantages over intravenous administration due to their lack of systemic absorption into the bloodstream, targeting the drug to the GI tract to rapidly neutralise and clear the infection.
Oral antibodies to promote a healthy, functioning body
The company currently markets its flagship commercial products, Travelan® and Protectyn®, in Australia, where both products are listed as medicines on the Australian Register for Therapeutic Goods.
Travelan® (AUST L 106709) is an over-the-counter, orally administered passive immunotherapeutic product indicated to reduce the risk of travellers’ diarrhoea, minor gastrointestinal disorders, and antimicrobials. It is sold in pharmacies throughout Australia.
Protectyn® (AUST L 231001) is currently sold in practitioners’ offices and is marketed as an immune supplement that helps maintain healthy digestive and liver function.
Travelan®
Travelan®’s active ingredient is hyperimmune bovine colostrum powder, a natural and rich source of oral antibodies that bind to Enterotoxigenic E. coli and other diarrhoea-causing bacteria in the gastrointestinal tract.
Travelan® helps to stop these bacteria from attaching to the intestinal wall and neutralises their ability to cause diarrhoea, digestive upset, and other associated symptoms.
The hyperimmune colostrum in Travelan® is developed under Immuron’s proprietary technology to create high titres of antibodies to a range of E. coli bacteria. This makes Travelan® unique in its high levels of antibodies and sets it apart from normal bovine colostrum.
Protectyn®
Bacteria and LPS toxins disrupt the normal function of the gut, allowing them to pass into the bloodstream, where they can trigger inflammation that can cause many diseases.
Protectyn® is a natural formulation of hyperimmune bovine colostrum enriched with anti-LPS oral antibodies. These antibodies enter the digestive system and target harmful bacteria and their LPS toxins. Once bound by the antibodies in Protectyn®, these harmful elements can be safely removed from the body.
Therefore, by removing these bacteria and LPS toxins, Protectyn® helps restore gut balance, maintain healthy digestive function and support liver health.
Protectyn® also contains other components naturally occurring in colostrum, which have been shown to reduce inflammation in the body and provide digestive and liver health benefits.
Pipeline
Immuron is pursuing multiple research and development pathways to realise the potential of its proprietary technology platform.
The company presently has two drug candidates in clinical development and one in early-stage preclinical development.
Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for Clostridioides difficile (C.difficle) infections, vancomycin resistant enteroccoi (VRE) infections Enterotoxigenic Escherichia coli (ETEC) infections, shigellosis (bacillary dysentery) and traveller’s diarrhoea (a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce).
